- Molecular NameBenztropine
- SynonymBenzatropina [INN-Spanish]; Benzatropine; Benzatropine mesilate; Benzatropinum [INN-Latin]; Benztropine Mesylate; Benztropinum; Tropine Benzohydryl Ether
- Weight307.437
- Drugbank_IDDB00245
- ACS_NO86-13-5
- Show 3D model
- LogP (experiment)3.75
- LogP (predicted, AB/LogP v2.0)4.6
- pkaN/A
- LogD (pH=7, predicted)1.67
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)-1.27
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.07
- No.of HBond Donors0
- No.of HBond Acceptors2
- No.of Rotatable Bonds4
- TPSA12.47
- StatusFDA approved
- AdministrationOral, IM, IV
- PharmacologyAn anticholinergic drug principally used for the treatment of: Drug-induced parkinsonism, akathisia and acute dystonia; Parkinson disease; and Idiopathic or secondary dystonia.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability29.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmBenztropine has been reported to undergo N-oxidation, N-dealkylation and ring hydroxylation in rats
- Half life36 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySigns of overdose include confusion, nervousness, listlessness, hallucinations, dizziness; muscle weakness, ataxia, dry mouth, mydriasis, blurred vision, palpitations, tachycardia, elevated blood pressure, nausea, vomiting, dysuria, numbness of fingers, headache, delirium, coma, shock, convulsions, respiratory arrest, anhidrosis, hyperthermia, glaucoma, and constipation.
- LD50 (rat)N/A
- LD50 (mouse)N/A